Pharmac has purchased another new medicine, baricitinib, to treat moderate to severe cases of COVID-19, with 500 courses expected in New Zealand within a matter of week
The final report of the Government’s review into drug-buying agency Pharmac has been delayed by nearly three months, with a new release date set for early next year
The Youth19 survey of secondary school students shows 10 per cent are regular vapers, and 50 per cent of them had not smoked a cigarette before vaping.
The risks posed by New Zealand’s expanding COVID-19 epidemic meant Pharmac needed to move faster than its normal processes permit in deciding to fund a new medicine for the disease, says the agency’s new chief medical officer.
The Health Quality & Safety Commission has been funding DHBs to reduce harm from failures to recognise and respond to acute physical deterioration in adult in-patients.
Pharmac has funded upadacitinib tablets as an alternative treatment for New Zealanders with severe rheumatoid arthritis, who are impacted by the tocilizumab stock shortage
Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management